MacroGenics Reaches Analyst Target Price

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Markets MGNX MacroGenics Reaches Analyst Target Price March 11, 2026 — 06:44 am EDT Written by BNK Invest for BNK Invest-> In recent trading, shares of MacroGenics, Inc (Symbol: MGNX) have crossed above the average analyst 12-month target price of $3.40, changing hands for $3.43/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 5 different analyst targets within the Zacks coverage universe contributing to that average for MacroGenics, Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $2.00. And then on the other side of the spectrum one analyst has a target as high as $5.00. The standard deviation is $1.14. But the whole reason to look at the average MGNX price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with MGNX crossing above that average target price of $3.40/share, investors in MGNX have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $3.40 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover MacroGenics, Inc: Recent MGNX Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 3 3 3 4 Buy ratings: 0 0 0 0 Hold ratings: 6 6 6 5 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 2.33 2.33 2.33 2.11 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on MGNX — FREE. The Top 25 Broker Analyst Picks of the S&P 500 » Also see: • EZPW Average Annual Return • Top Ten Hedge Funds Holding OSK • AZYO shares outstanding history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags MarketsStocksETFs BNK Invest BNK Invest Inc. provides investment services and information. BNK Invest owns and operates a market news family of websites including DividendChannel, ETFChannel, StockOptionsChannel, and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual investors internationally. EZPW Average Annual Return-> Top Ten Hedge Funds Holding OSK-> AZYO shares outstanding history-> More articles by this source-> Stocks mentioned MGNX More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.